NCT02688712 2026-04-13
ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer
Providence Health & Services
Phase 2 Active not recruiting
Clinical Trials
10 trialsNCT05700656 2024-07-22
Galunisertib Combined With Capecitabine in Advanced CRC With PM
The Netherlands Cancer Institute
Phase 1/2 Recruiting
NCT02178358 2022-02-25
A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma
Eli Lilly and Company
Phase 2 Completed
NCT02423343 2021-09-09
A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma
Eli Lilly and Company
Phase 1/2 Completed
NCT01246986 2021-01-12
A Study of LY2157299 in Participants With Hepatocellular Carcinoma
Eli Lilly and Company
Phase 2 Completed
NCT02240433 2020-02-05
A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC)
Eli Lilly and Company
Phase 1 Completed
NCT02734160 2019-08-05
A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer
Eli Lilly and Company
Phase 1 Completed
NCT03470350 2019-07-24
EORTC1615
The Netherlands Cancer Institute
Phase 1/2 Withdrawn
NCT01373164 2018-05-16
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Eli Lilly and Company
Phase 1/2 Completed
NCT02154646 2016-02-10
A Study of LY2157299 in Participants With Pancreatic Cancer That is Advanced or Has Spread to Another Part of the Body
Eli Lilly and Company
Phase 1 Completed